R
Ruixin Intelligent Medical Technology
AI-powered cardiovascular diagnosis and surgical robotics.
About Ruixin Intelligent Medical Technology
Shenzhen Ruixin Intelligent Medical Technology Co., Ltd. (Raysightmed) is a medical technology company founded in December 2017. Headquartered in Shenzhen, China, the company specializes in developing intelligent diagnosis and treatment solutions for cardiovascular, cerebrovascular, and peripheral vascular diseases. Raysightmed operates on a B2B model, providing its technology to hospitals and clinical partners. The company's product portfolio includes RuiXin-FFR, a non-invasive diagnostic system for assessing coronary artery blood flow (NMPA and CE certified), RuiXin-CoronaryAI for intelligent CT image processing, AngioQFA for intraoperative functional assessment, and RuiXin-Planner for preoperative surgical planning. A significant innovation is their fully automatic AI vascular interventional surgical robot, which allows doctors to issue natural language commands for automated surgical operations, aiming to automate repetitive procedures and assist in complex surgeries. Raysightmed has raised $7.02 million over three funding rounds, with investors including Matrix Partners China, China Growth Capital, and Tencent. The company has collaborated with over 800 hospitals, holds more than 200 patents, and its products have been used in over 200,000 cases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Shenzhen, China
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 25.0/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Surgery, Cardiology and cardiovascular, Surgical Equipment, DT and LS, science-based
- Technology
- Artificial Intelligence, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES D✓Equity / VC | May 2026 | $14M | $440M | Guangzhou Yuefu Fund Management · Guangzhou Jinkong Fund | ↗ |
| SERIES A✓Equity / VC | Jan 2019 | $3M | $12M | Matrix Partners China | — |
Growth signals
Latest recorded traffic for Ruixin Intelligent Medical Technology is 680 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
Series B and later2 investors entered at this stage
- GFGuangzhou Jinkong Fund
- GMGuangzhou Yuefu Fund Management
Other known investors1 additional known investor
Huarong Yufu Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Ruixin Intelligent Medical Technology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Ruixin Intelligent Medical Technology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.